ATE399537T1 - Pharmazeutische zusammensetzungen mit atorvastatin, hergestellt ohne granulation - Google Patents
Pharmazeutische zusammensetzungen mit atorvastatin, hergestellt ohne granulationInfo
- Publication number
- ATE399537T1 ATE399537T1 AT04735619T AT04735619T ATE399537T1 AT E399537 T1 ATE399537 T1 AT E399537T1 AT 04735619 T AT04735619 T AT 04735619T AT 04735619 T AT04735619 T AT 04735619T AT E399537 T1 ATE399537 T1 AT E399537T1
- Authority
- AT
- Austria
- Prior art keywords
- granulation
- produced
- pharmaceutical compositions
- compositions containing
- containing atorvastatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47791803P | 2003-06-12 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE399537T1 true ATE399537T1 (de) | 2008-07-15 |
Family
ID=33551781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04735619T ATE399537T1 (de) | 2003-06-12 | 2004-06-01 | Pharmazeutische zusammensetzungen mit atorvastatin, hergestellt ohne granulation |
Country Status (23)
Country | Link |
---|---|
US (2) | US20050271717A1 (de) |
EP (2) | EP1977738A1 (de) |
JP (1) | JP2006527256A (de) |
KR (1) | KR20060028768A (de) |
CN (1) | CN100446757C (de) |
AR (1) | AR044775A1 (de) |
AT (1) | ATE399537T1 (de) |
AU (1) | AU2004246866A1 (de) |
BR (1) | BRPI0411079A (de) |
CA (1) | CA2465621A1 (de) |
CO (1) | CO5640072A2 (de) |
DE (1) | DE602004014765D1 (de) |
DK (1) | DK1635791T3 (de) |
ES (1) | ES2305775T3 (de) |
MX (1) | MXPA05013392A (de) |
NO (1) | NO20055185L (de) |
PL (1) | PL1635791T3 (de) |
PT (1) | PT1635791E (de) |
RU (1) | RU2314804C2 (de) |
SI (1) | SI1635791T1 (de) |
TW (1) | TW200509905A (de) |
WO (1) | WO2004110409A1 (de) |
ZA (1) | ZA200509906B (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
EP1937642B1 (de) | 2005-10-19 | 2014-09-10 | Teva Pharmaceutical Industries Ltd | Kristalle von laquinimod-natrium und verfahren zu deren herstellung |
EP1810667A1 (de) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin |
WO2007146248A2 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
DE102007052071A1 (de) * | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
ES2600920T3 (es) | 2007-12-20 | 2017-02-13 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
WO2009116061A2 (en) * | 2008-01-10 | 2009-09-24 | Alkem Laboratories Ltd. | Stable oral pharmaceutical composition comprising atorvastatin |
GB0800788D0 (en) * | 2008-01-16 | 2008-02-27 | Glaxo Group Ltd | Niovel formulation |
CA2637977A1 (en) * | 2008-07-15 | 2010-01-15 | Pharmascience Inc. | Dosage form containing a statin |
AU2009288108B2 (en) * | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
HUE027680T2 (en) * | 2009-07-30 | 2016-11-28 | Teva Pharma | Treatment of Crohn's disease with laquinimod |
PL3064206T3 (pl) * | 2009-08-10 | 2020-02-28 | Active Biotech Ab | Leczenie choroby Huntingtona z zastosowaniem lakwinimodu |
US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
EP2916915A4 (de) | 2012-11-07 | 2016-06-22 | Teva Pharma | Aminsalze von laquinimod |
MX2015011627A (es) | 2013-03-14 | 2016-05-16 | Teva Pharma | Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos. |
KR20200109291A (ko) * | 2017-08-18 | 2020-09-22 | 애브비 인코포레이티드 | 자궁내막증, 자궁섬유증, 다낭난소증후군 또는 샘근육증을 치료하기 위한 약제학적 제형 |
US11980627B2 (en) * | 2019-06-14 | 2024-05-14 | Joshua O. Atiba | Triple pharmaceutical composition for proteinaceous infection |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
CA2150372C (en) * | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
EE03606B1 (et) * | 1995-07-17 | 2002-02-15 | Warner-Lambert Company | Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
CN1093126C (zh) * | 1996-07-29 | 2002-10-23 | 沃尼尔·朗伯公司 | 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法 |
GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
ATE360608T1 (de) * | 1997-12-19 | 2007-05-15 | Pfizer Ireland Pharmaceuticals | Verfahren zur herstellung von 1,3-diolen |
US6287594B1 (en) * | 1998-01-20 | 2001-09-11 | Edward S. Wilson | Oral liquid compositions |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
IN191236B (de) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
EP2206497A1 (de) | 1999-11-17 | 2010-07-14 | Teva Pharmaceutical Industries Ltd. | Polymorphe Formen von Atorvastatin calcium |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
CA2406574C (en) | 2000-04-10 | 2006-12-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
CA2426632C (en) | 2000-11-03 | 2008-08-05 | Teva Pharmaceutical Industries, Ltd. | Atorvastatin hemi-calcium form vii |
CA2427255A1 (en) | 2000-11-16 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2626317A1 (en) | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
EP1243524A3 (de) | 2001-03-16 | 2004-04-07 | Pfizer Products Inc. | Pharmazeutisches Kit fÜr sauerstoffempfindliche Medikamente |
EP1241110A1 (de) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Ausgabeeinheit für sauerstoff-empfindlichen Medikamenten |
IN190564B (de) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
RS100003A (en) * | 2001-06-29 | 2007-02-05 | Warner-Lambert Company, | Crystalline forms of /r-(r*,r*)-2-(4- fluorphenyl)-beta,delta -dihydroxy-5(1- methylethyl)-phenyl-4-/phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
KR20040019043A (ko) | 2001-07-30 | 2004-03-04 | 닥터 레디스 레보러터리즈 리미티드 | 아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ |
CA2456732C (en) * | 2001-08-07 | 2012-10-30 | Galephar M/F | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor |
UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
MXPA04007905A (es) * | 2002-02-14 | 2004-11-26 | Ranbaxy Lab Ltd | Formulaciones de atorvastatin estabilizadas con adiciones de metal alcali. |
EP1480950A4 (de) | 2002-02-15 | 2005-05-18 | Teva Pharma | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
AU2002330735A1 (en) | 2002-09-03 | 2004-03-29 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
-
2004
- 2004-04-20 US US10/828,419 patent/US20050271717A1/en not_active Abandoned
- 2004-04-29 CA CA002465621A patent/CA2465621A1/en not_active Abandoned
- 2004-06-01 PT PT04735619T patent/PT1635791E/pt unknown
- 2004-06-01 JP JP2006516504A patent/JP2006527256A/ja active Pending
- 2004-06-01 SI SI200430802T patent/SI1635791T1/sl unknown
- 2004-06-01 DE DE602004014765T patent/DE602004014765D1/de not_active Revoked
- 2004-06-01 RU RU2005138496/15A patent/RU2314804C2/ru not_active IP Right Cessation
- 2004-06-01 WO PCT/IB2004/001845 patent/WO2004110409A1/en active IP Right Grant
- 2004-06-01 DK DK04735619T patent/DK1635791T3/da active
- 2004-06-01 AU AU2004246866A patent/AU2004246866A1/en not_active Abandoned
- 2004-06-01 ES ES04735619T patent/ES2305775T3/es not_active Expired - Lifetime
- 2004-06-01 KR KR1020057023838A patent/KR20060028768A/ko active IP Right Grant
- 2004-06-01 EP EP08153178A patent/EP1977738A1/de not_active Withdrawn
- 2004-06-01 MX MXPA05013392A patent/MXPA05013392A/es unknown
- 2004-06-01 CN CNB2004800143122A patent/CN100446757C/zh not_active Expired - Fee Related
- 2004-06-01 EP EP04735619A patent/EP1635791B1/de not_active Revoked
- 2004-06-01 AT AT04735619T patent/ATE399537T1/de not_active IP Right Cessation
- 2004-06-01 BR BRPI0411079-0A patent/BRPI0411079A/pt not_active IP Right Cessation
- 2004-06-01 PL PL04735619T patent/PL1635791T3/pl unknown
- 2004-06-10 AR ARP040102010A patent/AR044775A1/es unknown
- 2004-06-11 TW TW093116996A patent/TW200509905A/zh unknown
-
2005
- 2005-11-04 NO NO20055185A patent/NO20055185L/no not_active Application Discontinuation
- 2005-12-06 ZA ZA200509906A patent/ZA200509906B/en unknown
- 2005-12-12 CO CO05125195A patent/CO5640072A2/es not_active Application Discontinuation
-
2009
- 2009-05-08 US US12/424,972 patent/US20090226510A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PT1635791E (pt) | 2008-09-10 |
NO20055185D0 (no) | 2005-11-04 |
CO5640072A2 (es) | 2006-05-31 |
CA2465621A1 (en) | 2004-12-12 |
PL1635791T3 (pl) | 2008-11-28 |
AR044775A1 (es) | 2005-10-05 |
RU2314804C2 (ru) | 2008-01-20 |
EP1977738A1 (de) | 2008-10-08 |
CN1794978A (zh) | 2006-06-28 |
KR20060028768A (ko) | 2006-04-03 |
SI1635791T1 (sl) | 2008-10-31 |
JP2006527256A (ja) | 2006-11-30 |
EP1635791B1 (de) | 2008-07-02 |
EP1635791A1 (de) | 2006-03-22 |
RU2005138496A (ru) | 2006-04-27 |
NO20055185L (no) | 2006-03-09 |
US20050271717A1 (en) | 2005-12-08 |
BRPI0411079A (pt) | 2006-07-25 |
DK1635791T3 (da) | 2008-08-25 |
US20090226510A1 (en) | 2009-09-10 |
TW200509905A (en) | 2005-03-16 |
CN100446757C (zh) | 2008-12-31 |
ZA200509906B (en) | 2007-01-31 |
AU2004246866A1 (en) | 2004-12-23 |
DE602004014765D1 (de) | 2008-08-14 |
MXPA05013392A (es) | 2006-03-09 |
WO2004110409A1 (en) | 2004-12-23 |
ES2305775T3 (es) | 2008-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE399537T1 (de) | Pharmazeutische zusammensetzungen mit atorvastatin, hergestellt ohne granulation | |
DK1615646T4 (da) | Farmaceutiske formuleringer, der indeholder methylnaltrexon | |
DE60307677D1 (de) | Dispergierbare pharmazeutische zusammensetzungen | |
FI20011478A (fi) | Farmaseuttinen koostumus | |
ATE460169T1 (de) | Pharmazeutische formulierung mit lanthanum- verbindungen | |
DE60127002D1 (de) | Pharmazeutische zusammensetzung | |
ATE307571T1 (de) | Pharmazeutische formulierung enthaltend bicalutamid | |
PT1501534E (pt) | Formulacoes farmaceuticas | |
ATE334656T1 (de) | Flüssige pharmazeutische zusammensetzung | |
AT7729U3 (de) | Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat | |
PT1467724E (pt) | Composicao farmaceutica orodispersavel de agomelatina | |
DE60210139D1 (de) | Pharmazeutische zusammensetzungen enthaltend tegaserod | |
DE602004016967D1 (de) | Flüssige pharmazeutische palonosetronformulierungen | |
DE60312049D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
DK1587478T3 (da) | Farmaceutisk sammensætning | |
DK1643976T3 (da) | Farmaceutisk formulering omfattende levothyroxinnatrium | |
FI20022128A0 (fi) | Farmaseuttinen koostumus | |
DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
ATE366128T1 (de) | Pharmazeutische zusammensetzung | |
DE60310526D1 (de) | Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion | |
ATE546141T1 (de) | Pharmazeutisches injektionspräparat | |
DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
ATE350029T1 (de) | Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain | |
DE10107261B4 (de) | Pharmazeutische Zusammensetzung | |
NO20044164L (no) | Farmasoytiske sammensetninger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1635791 Country of ref document: EP |
|
RZN | Patent revoked |